



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

# Vaccine

journal homepage: [www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)

## Editorial

# 100 years of the Bacillus Calmette-Guérin vaccine



On July 18, 2021, the world celebrated the 100th anniversary of the first administration of Bacillus Calmette-Guérin (BCG), the only licensed vaccine against tuberculosis (TB) to date. Since its introduction a century ago, billions of people have been vaccinated with BCG, leading to an extraordinary drop in overall infant mortality, likely not only due to a reduction in TB, but also, other infections. Yet, although the efficacy of BCG to prevent TB meningitis and disseminated TB in children is well established, its efficacy to prevent contagious TB in adolescents and adults is uncertain, and novel TB vaccines are urgently needed.

Extraordinary progress has been made during the past century in life sciences, with the knowledge about BCG increasing in parallel, as witnessed by more than 30,000 citations found on PubMed. From efficacy studies against TB to treatment of bladder cancer, BCG changed the world and still has plenty to offer. Yet, the exact mechanism that induces protection as well as the correlates of protection against TB are still poorly defined. With the current COVID-19 pandemic, BCG has re-gained increased attention due to its potential heterologous effects against non-mycobacterial pathogens, including SARS-CoV-2.

In this Special Issue, we present papers that discuss the strengths and limitations of this vaccine, the diversity of applications, its broad protection against a plethora of diseases and the current efforts to improve it. The Special Issue contains various types of articles, including research articles, review articles, editorials and a meeting report, covering a variety of topics, from historical perspectives on BCG and TB vaccine candidates to the most recent advances in BCG research and new TB vaccine strategies to modify, improve or boost BCG. Also, the immunology of BCG and the non-specific effects of BCG vaccination, both against heterologous infectious agents and non-infectious diseases, are discussed. Combined with the increasing problem of vaccine hesitancy throughout the world, this is a most relevant and timely topic, and a unique opportunity to show that vaccination works, requires further refinement and has a great future ahead.

Specifically, the issue focuses in the following topics: (i) a meeting report on the Virtual Global Forum on Tuberculosis Vaccines which includes historical perspectives on BCG and TB vaccine candidates [1]; (ii) heterologous effects of BCG against leprosy [2], SARS-CoV-2 [3] and Buruli ulcer [4]; (iii) Pre/post-exposure vaccination (including therapeutic vaccination): new vaccination strategies to modify or improve BCG [5], sex differences in the protective efficacy of BCG [6], and a novel vaccine candidate (MTBVAC) which is on the cusp of initiating efficacy trials [7]; (iv) The effects of neonatal BCG vaccination on mortality up to 1 year of age [8];

(v) Unconventional T cells & BCG vaccination: How important are Donor Unrestricted T cells (DURT) in protection? To what extent does BCG induce or limit DURT expansion? [9]; (vi) Usage of BCG in diverse therapeutic settings including bladder cancer [10–12], more broadly as oncotherapy [13], as well as allergic asthma [14] and endometriosis [15].

Currently, there are more than 12 vaccines against TB in clinical trials, including repeated BCG vaccination, which is the confirmation that despite being 100 years old, the BCG vaccine is here to stay. Altogether, we hope that this special issue will stimulate future research in TB vaccine development.

## References

- [1] Suliman S, Pelzer PT, Shaku M, Rozot V, Mendelsohn SC. Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20–22 April 2021. *Vaccine* 2021;39:7223–9.
- [2] van Hooij A, van den Eeden SJF, Khatun M, Soren S, Franken KLMC, Chandra Roy J, et al. BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease. *Vaccine* 2021;39:7230–7.
- [3] Pépin J, Labbé AC, Carignan A, Parent ME, Yu J, Grenier C, et al. Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada. *Vaccine* 2021;39:7300–07.
- [4] Muhi S, Stinear TP. Systematic review of *M. Bovis* BCG and other candidate vaccines for Buruli ulcer prophylaxis. *Vaccine* 2021;39:7238–52.
- [5] Heijmenberg I, Husain A, Sathkumara HD, Muruganandah V, Seifert J, Miranda-Hernandez S, et al. ESX-5-targeted export of ESAT-6 in BCG combines enhanced immunogenicity & efficacy against murine tuberculosis with low virulence and reduced persistence. *Vaccine* 2021;39:7265–76.
- [6] Nieuwenhuizen NE, Zyla J, Zedler U, Bandermann S, Abu Abed U, Brinkmann V, et al. Weaker protection against tuberculosis in BCG-vaccinated male 129 S2 mice compared to females. *Vaccine* 2021;39:7253–64.
- [7] Martín C, Marinova D, Aguiló N, Gonzalo-Asensio J. MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG. *Vaccine* 2021;39:7277–85.
- [8] Schaltz-Buchholzer F, Roth A, de Bree LCJ, Biering-Sørensen S, Timmermann CAG, Monteiro I, et al. Neonatal Bacille Calmette-Guérin vaccination and tuberculin skin test reactions at 2- and 6-months: Effects on mortality up to 1 year of age. *Vaccine* 2021;39:7286–94.
- [9] Soma S, Lewinsohn DA, Lewinsohn DM. Donor Unrestricted T Cells: Linking innate and adaptive immunity. *Vaccine* 2021;39:7295–99.
- [10] Lamm DL, Morales A. A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment. *Vaccine* 2021;39:7308–18.
- [11] von Reyn CF. BCG versus rBCG: what is the way forward? *Vaccine* 2021;39:7319–20.
- [12] Singh AK, Srikrishna G, Bivalacqua TJ, Bishai WR. Recombinant BCGs for tuberculosis and bladder cancer. *Vaccine* 2021;39:7321–31.
- [13] Mukherjee N, Julián E, Torresles JB, Svatek RS. Effects of *Mycobacterium bovis* Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond. *Vaccine* 2021;39:7332–40.
- [14] Kowalewicz-Kulbat M, Loch C. BCG for the prevention and treatment of allergic asthma. *Vaccine* 2021;39:7341–52.
- [15] Hecht J, Suliman S, Wegiel B. Bacillus Calmette-Guérin (BCG) vaccination to treat endometriosis. *Vaccine* 2021;39:7353–6.

Paulo J.G. Bettencourt\*  
Catholic University of Portugal, Lisbon, Portugal

Centre for Interdisciplinary Research in Health, Catholic University of  
Portugal, Lisbon, Portugal

\* Corresponding author at: Catholic University of Portugal, Lisbon,  
Portugal.

E-mail address: [pbettencourt@ucp.pt](mailto:pbettencourt@ucp.pt)

Simone A. Joosten  
Department of Infectious Diseases, Leiden University Medical Center,  
Leiden, Netherlands

Cecilia S. Lindestam Arlehamn  
Center for Infectious Disease and Vaccine Research, La Jolla Institute for  
Immunology, La Jolla, CA, USA

Marcel A. Behr  
Department of Microbiology & Immunology, McGill University, Mon-  
tréal, Canada

Infectious Diseases and Immunity in Global Health Program, Research  
Institute of the McGill University Health Centre, Montréal, Canada

McGill International TB Centre, Montréal, Canada

Department of Medicine, McGill University Health Centre, Montréal,  
Canada

Camille Locht  
Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille,  
U1019 - UMR 9017 - CIL - Center for Infection and Immunity of Lille,  
Lille, F-59000, France

Olivier Neyrolles  
Institut de Pharmacologie et Biologie Structurale, Université de Toulouse,  
CNRS, UPS, Toulouse, France

Available online 22 November 2021